This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mohr, D. C Articles by Goodkin, D. E Search for Related Content PubMed PubMed Citation Articles by Mohr, D. C Articles by Goodkin, D. E Social Bookmarking                         What's this?

Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la

University of California, San Francisco, Mt. Zion MS Center, 1600 Divisadero Street, San Francisco, California 941151642, USA

William Likosky

Kaiser Permancnic Medical Care Program, 1800 Harrison Street #410, Oakland, California 94612, USA

Arne C Boudewyn

University of California, San Francisco, Mt. Zion MS Center, 1600 Divisadero Street, San Francisco, California 941151642, USA

Peter Marietta

University of California, San Francisco, Mt. Zion MS Center, 1600 Divisadero Street, San Francisco, California 941151642, USA

Pat Dwyer

University of California, San Francisco, Mt. Zion MS Center, 1600 Divisadero Street, San Francisco, California 941151642, USA

Judy Van Der Wende

University of California, San Francisco, Mt. Zion MS Center, 1600 Divisadero Street, San Francisco, California 941151642, USA

Donald E Goodkin

University of California, San Francisco, Mt. Zion MS Center, 1600 Divisadero Street, San Francisco, California 941151642, USA

This study examines the course of patient-reported side effect during the first 4 months of treatment for multiple sclerosis (MS) with interferon beta-Ia (IFNß-Ia), and the relationship of those side effects to discontinuation of medication. Flu-like symptoms, muscle aches and chills decreased over the first 2 months of treatment but did not change over the second 2 months. Loss of feeling or numbness, tingling and depression increased over 4 months, however these side effects were generally mild. Loss of feeling or numbness and tingling at 2 month follow-up were significantly related to discontinuation of IFNß-Ia by 4 month follow-up.

Key Words: interferon • multiple sclerosis • side effects • compliance

Multiple Sclerosis, Vol. 4, No. 6, 487-489 (1998)
DOI: 10.1177/135245859800400605


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G Giovannoni, O Barbarash, F Casset-Semanaz, J King, L Metz, G Pardo, J Simsarian, P. Sorensen, B Stubinski, and on behalf of the Rebif(R) New Formulation Study Gr Safety and immunogenicity of a new formulation of interferon {beta}-1a (Rebif(R) New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results Multiple Sclerosis, February 1, 2009; 15(2): 219 - 228. [Abstract] [PDF]

				S Minden, D Hoaglin, S Jureidini, L Hadden, D Frankel, Y Komatsuzaki, and J Outley Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study Multiple Sclerosis, June 1, 2008; 14(5): 640 - 655. [Abstract] [PDF]

				K E. O'Rourke and M Hutchinson Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns Multiple Sclerosis, February 1, 2005; 11(1): 46 - 50. [Abstract] [PDF]

				A. Langer-Gould, H. H. Moses, and T. J. Murray Strategies for managing the side effects of treatments for multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S35 - S41. [Abstract] [Full Text]

				S Di Legge, M C Piattella, C Pozzilli, P Pantano, F Caramia, I F Pestalozza, A Paolillo, and G L Lenzi Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis Multiple Sclerosis, June 1, 2003; 9(3): 302 - 306. [Abstract] [PDF]

				J. Reess, J. Haas, K. Gabriel, A. Fuhlrott, and M. Fiola Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-la (AVONEX(R)) therapy Multiple Sclerosis, September 1, 2002; 8(1_suppl): 15 - 18. [Abstract] [PDF]

				I. S. Ockene, L. L. Hayman, R. C. Pasternak, E. Schron, and J. Dunbar-Jacob Task Force #4--adherence issues and behavior changes: achieving a long-term solution J. Am. Coll. Cardiol., August 21, 2002; 40(4): 630 - 640. [Full Text] [PDF]

				J Reess, J Haas, K Gabriel, A Fuhlrott, and M Fiola Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX(R)) therapy Multiple Sclerosis, February 1, 2002; 8(1): 15 - 18. [Abstract] [PDF]

				A. Feinstein Multiple sclerosis, disease modifying treatments and depression: a critical methodological review Multiple Sclerosis, October 1, 2000; 6(5): 343 - 348. [Abstract] [PDF]

				K Gottberg, A Gardulf, and S Fredrikson Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects Multiple Sclerosis, October 1, 2000; 6(5): 349 - 354. [Abstract] [PDF]

				D. C. Mohr, W. Likosky, P. Dwyer, J. Van Der Wende, A. C. Boudewyn, and D. E. Goodkin Course of Depression During the Initiation of Interferon Beta-1a Treatment for Multiple Sclerosis Arch Neurol, October 1, 1999; 56(10): 1263 - 1265. [Abstract] [Full Text] [PDF]